PharmaEssentia Corp (藥華醫藥) yesterday said that it has applied for marketing approval for its ropeginterferon alfa-2b drug with the China National Medical Products Administration.
The company seeks approval to use the treatment for a rare type of blood cancer, polycythemia vera, it said in a regulatory filing.
The interferon drug, sold in the US under the name Besremi, is the only approved first-line treatment for polycythemia vera, with its sole competitor being the US-based Incyte Corp’s Jakafi, which has been approved as second-line treatment.
Photo: Reuters
The drug has gained approval to be used in the treatment of adult polycythemia vera patients in Taiwan, Switzerland, Israel, South Korea, the US and the EU.
The company in October said that it was targeting China and Japan as the drug’s next markets.
PharmaEssentia did not specify the estimated date of completion for the marketing application, saying in the filing that it is subject to the Chinese agency’s procedures for case acceptance.
There are about 400,000 polycythemia vera patients in China, the company added.
Polycythemia vera is a chronic, progressive myeloproliferative neoplasm, and it is primarily characterized by a high count of red blood cells, PharmaEssentia said.
The blood disorder could result in cardiovascular complications, such as thrombosis and embolism, and often develops into secondary myelofibrosis or leukemia, it said.
Besremi is PharmaEssentia’s most significant product, helping boost its revenue 383.44 percent year-on-year to NT$2.63 billion (US$85.65 million) in the first 11 months of last year, company data showed.
The company reported a net loss of NT$1.22 billion in the first three quarters of last year, due to higher marketing, management, and research and development costs.
That translated into losses per share of NT$4.37, company data showed.
Analysts said the new drug would lead to robust sales growth and operating leverage in the long term.
The company is also conducting a phase 3 clinical trial for the drug to treat essential thrombocythemia, a rare disorder in which the bone marrow produces too many platelets.
PharmaEssentia yesterday in a separate filing said that it has received positive opinions from the Data and Safety Monitoring Board for the trial.
The board comprises independent experts who review clinical study data for new drugs.
It confirmed the safety of the trial and recommended that the firm continue conducting it according to protocols, PharmaEssentia said.
Essential thrombocythemia is a myeloproliferative neoplasm characterized by an overproduction of platelets in the blood resulting from a genetic mutation.
The number of people with essential thrombocythemia is similar to those with polycythemia vera, the company said.
PharmaEssentia has registered 90 percent enrollment for the trial and plans to complete it as soon as possible, it added.
The company’s shares rose 62.8 percent last year, closing at NT$477 on Friday in Taipei trading.
The stock last month joined MSCI Global Standard Indices after it made considerable gains last year, global index provider MSCI Inc has said.
DAMAGE REPORT: Global central banks are assessing war-driven inflation risks as the law of unintended consequences careens around the world, spiking oil prices Central banks from Washington to London and from Jakarta to Taipei are about to make their first assessments of economic damage after more than two weeks of conflict between the US and Iran. Decisions this week encompassing every member of the G7 and eight of the world’s 10 most-traded currency jurisdictions are likely to confirm to investors that the specter of a new inflation shock is already worrying enough to prompt heightened caution. The US Federal Reserve is widely expected to do exactly what everyone anticipated weeks ahead of its March 17-18 policy gathering: hold rates steady. The narrative surrounding that
PRICE HIKES: The war in the Middle East would not significantly disrupt supply in the short term, but semiconductor companies are facing price surges for materials Taiwan’s semiconductor companies are not facing imminent supply disruptions of essential chemicals or raw materials due to the war in the Middle East, but surges in material costs loom large, industry association SEMI Taiwan said yesterday. The association’s comments came amid growing concerns that supplies of helium and other key raw materials used in semiconductor production could become a choke point after Qatar shut down its liquefied natural gas (LNG) production and helium output earlier this month due to the conflict. Qatar is the second-largest LNG supplier in the world and accounts for about 33 percent of global helium output. Helium is
About 1,000 participants, including more than 200 venture capitalists, joined the Taiwan Demo Day in Silicon Valley on Saturday, the largest iteration to date of the event held ahead of Nvidia Corp’s annual GPU Technology Conference which runs from today to Thursday. Taiwan Demo Day, co-organized by the Taiwan Next Foundation and the Startup Island Taiwan Silicon Valley Hub, took place at the Computer History Museum in California, showcasing 12 teams focused on physical artificial intelligence (AI) and agentic AI technologies. Katie Hsieh (謝凱婷), founder of the Taiwan Next Foundation, said the event highlighted the strength of the Taiwan-US start-up ecosystem, with
DOMESTIC COMPONENT: Huang identified several Taiwanese partners to be a key part of Nvidia’s Vera Rubin supply chain, including Asustek, Hon Hai and Wistron Nvidia Corp chief executive officer Jensen Huang (黃仁勳), addressing crowds at the company’s biggest annual event, unveiled a variety of new products while predicting that its flagship artificial intelligence (AI) processors would help generate US$1 trillion in sales through next year. During a two-and-a-half-hour keynote address, Huang announced plans to push deeper into central processing units (CPUs) — Intel Corp’s home turf — and introduced semiconductors made with technology acquired from start-up Groq Inc. The company even said it was developing chips for data centers in outer space. At the heart of Huang’s speech was the message that demand for computing power
RSS